AMT: A Key Protein in The Endocannabinoid System (P33507)

Target Name: Anandamide membrane transporter (AMT)

NCBI ID: P33507

Anandamide membrane transporter (AMT)

Other Name(s): AMT

AMT: A Key Protein in The Endocannabinoid System

Anandamide membrane transporter (AMT), also known as endocannabinoid receptor 2 (ECR2), is a protein that plays a crucial role in the endocannabinoid system (ECS). The ECS is a complex cell-signaling system that regulates various physiological processes in the body , including mood, pain, inflammation, and sleep. AMT is one of the key proteins that enables the ECS to function properly.

AMT is a transmembrane protein that is expressed in various tissues and cells throughout the body. It is primarily located in the endoskeleton, which is a specialized membrane-bound organ that plays a vital role in the ECS. The endoskeleton is responsible for producing and storing anandamide, which is a naturally occurring compound that plays a crucial role in the body's mood, appetite, and pain perception.

AMT is a key transporter for anandamide, which means that it enables the efficient delivery of anandamide across the endoskeleton membrane. When anandamide is released from the endoskeleton, it binds to AMT, which then transports it to the endoskeleton's interior. There, anandamide can interact with other endocannabinoids, such as 2-arachidonoylglycerol (2-AG) and 2- fatty acid amide (2-FFA), leading to various physiological effects.

AMT is a protein that is composed of four transmembrane domains: a catalytic domain, a transmembrane domain, an intracellular domain, and an extracellular domain. The catalytic domain is responsible for the protein's catalytic activity, while the transmembrane domains are responsible for maintaining the protein's stability and functions as a transporter. The intracellular domain is responsible for interacting with the protein's intracellular targets, while the extracellular domain is responsible for interacting with the protein's extracellular targets.

AMT is a potent drug target, and various studies have identified its potential as a potential therapeutic agent for various diseases. For example, AMT has been shown to be a potential therapeutic for the treatment of depression, anxiety, and pain. Studies have shown that AMT inhibitors can improve the symptoms of depression and anxiety in animal models of these conditions.

AMT has also been shown to be a potential therapeutic for chronic pain, including neuropathic pain and pain associated with inflammatory diseases. For example, studies have shown that AMT inhibitors can alleviate pain in animal models of neuropathic pain and inflammatory pain.

AMT is also a potential biomarker for various diseases, including cancer. Studies have shown that AMT levels are often elevated in various types of cancer, and that inhibitors of AMT can be effective in treating these conditions. For example, studies have shown that inhibitors of AMT can reduce the growth of cancer cells in animal models.

In conclusion, AMT is a protein that plays a crucial role in the endocannabinoid system. Its function as a transporter for anandamide allows it to regulate the production and storage of anandamide, which is involved in various physiological processes in the body. AMT is a potent drug target and has been shown to be effective in treating a variety of conditions, including depression, anxiety, pain, and cancer. Further research is needed to fully understand the role of AMT in the ECS and its potential as a therapeutic agent.

Protein Name: Anandamide Membrane Transporter (AMT)

The "Anandamide membrane transporter (AMT) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Anandamide membrane transporter (AMT) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets